TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07136181: Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma

Sponsor: Novelwise Pharmaceutical Corporation · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 36 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$5,222,910

Rescue Site Savings

+$3,455,760

Unlock Full NCT07136181 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07136181 Rescue Dossier →